Cochrane · systematic review · CD010407
Bioidentical hormones for women with vasomotor symptoms
Gaudard, AMIS, Silva de Souza, S, Puga, MES, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
15
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 20%Low 9 · 60%Moderate 3 · 20%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Transdermal beta‐estradiol patch versus placebo for women with hot flushes
Population: women with hot flushes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of hot flushes Beta‐estradiol patch 0.0375‐0.10 mg/day Transdermal beta‐estradiol patch vs placebo | no estimate extracted | 4 studies · 793 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Intensity of hot flushes Beta‐estradiol patch 0.025‐0.05 mg/day Transdermal beta‐estradiol patch vs placebo | no estimate extracted | 2 studies · 393 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Adverse effects Beta‐estradiol patch dose 0.10 mg/day Transdermal beta‐estradiol patch vs placebo | OR 2.14 [1.29, 3.54] | 9 studies · 1822 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Transdermal beta‐estradiol gel versus placebo for women with hot flushes
Population: women with hot flushes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of hot flushes Beta‐estradiol gel 0.27‐1.5 mg/day Transdermal beta‐estradiol gel vs placebo | no estimate extracted | 3 studies · 930 participants | Low Downgraded: risk of bias |
Adverse effects Beta‐estradiol gel dose 1.5 mg/day Transdermal beta‐estradiol gel vs placebo | no estimate extracted | 3 studies · 1086 participants | Moderate Downgraded: risk of bias |
Oral beta‐estradiol versus placebo for women with hot flushes
Population: women with hot flushes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of hot flushes Oral beta‐estradiol 0.5‐1.0 mg/day Oral beta‐estradiol vs placebo | no estimate extracted | 2 studies · 356 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects Oral beta‐estradiol 0.5‐2.0 mg/day Oral beta‐estradiol vs placebo | no estimate extracted | 3 studies · 433 participants | Low Downgraded: risk of bias, imprecision |
Topical beta‐estradiol emulsion versus placebo for women with hot flushes
Population: women with vasomotor symptoms
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of vasomotor menopausal symptoms Micellar nanoparticle beta‐estradiol 8.6 mg/day Topical beta‐estradiol emulsion vs placebo | no estimate extracted | 1 study · 200 participants | Low Downgraded: risk of bias |
Adverse effects Micellar nanoparticle beta‐estradiol 8.6 mg/day Topical beta‐estradiol emulsion vs placebo | OR 1.46 [0.8, 2.66] | 1 study · 200 participants | Low Downgraded: risk of bias |
Intranasal beta‐estradiol versus placebo for women with hot flushes
Population: women with hot flushes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of hot flushes Change from baseline Intranasal beta‐estradiol 0.021 mg/day, 0.029 mg/day or 0.040 mg/day Intranasal beta‐estradiol vs placebo | no estimate extracted | 1 study · 458 participants | Moderate Downgraded: risk of bias |
Adverse effects Intranasal beta‐estradiol 0.021 mg/day, 0.029 mg/day or 0.040 mg/day Intranasal beta‐estradiol vs placebo | OR 1.96 [1.26, 3.03] | 1 study · 458 participants | Moderate Downgraded: risk of bias |
Transdermal beta‐estradiol patch versus conjugated equine estrogens for women with hot flushes
Population: women with hot flushes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of hot flushes Beta‐estradiol patch 0.05 or 0.1 mg per day vs CEE 0.625 or 1.25 mg per day Transdermal beta‐estradiol patch vs conjugated equine estrogens | no estimate extracted | 2 studies · 711 participants | Low Downgraded: risk of bias |
Adverse events Beta‐estradiol patch 0.05 or 0.1 mg/day vs CEE 0.625 or 1.25 mg/day Transdermal beta‐estradiol patch vs conjugated equine estrogens | no estimate extracted | 2 studies · 711 participants | Very low Downgraded: risk of bias |
Oral beta‐estradiol versus conjugated equine estrogens for women with hot flushes
Population: women with hot flushes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Frequency of hot flushes Oral beta‐estradiol 1.0 and 2.0 mg/day vs CEE 0.625 or 1.25 mg/day Oral beta‐estradiol vs conjugated equine estrogens | no estimate extracted | 1 study · 102 participants | Very low Downgraded: risk of bias |
Adverse events Oral beta‐estradiol 1.0 or 2.0 mg/day vs CEE 0.625 or 1.25 mg/day Oral beta‐estradiol vs conjugated equine estrogens | no estimate extracted | 1 study · 103 participants | Very low Downgraded: risk of bias, imprecision |